Lois M. Mulligan, Ph.D.
Office Phone: 613-533-6000 x77475
Professor of Pathology & Molecular Medicine, Paediatrics
Dr. Mulligan's Lab
The primary interests of our group is in the relationship between the processes of normal and neoplastic growth. We are interested in dissecting the genetic events responsible for diseases that disrupt normal developmental patterns. Our specific area of interest is in the role of the RET proto-oncogene.Mutations in the RET gene are involved in the inherited cancer syndromemultiple endocrine neoplasia type 2 (MEN 2) and also in a common birth defect which affects the formation of nerves in the developing gut. Early recognition of these diseases, by identifying RET mutations, allows treatment before symptoms or complications develop which reduces morbidity and death for these patients. However, not all disease cases have detectable RET mutations. We need to identify new genes or mechanisms that might account for these diseases cases and allow us to improve our ability to diagnose prevent or treat the disease in these patients. Our lab is investigating the normal functions of RET and the molecules with which it interacts in development of neural cell types and in tumours of neuorendocrine cell types.
Hyndman BD, Gujral TS, Krieger JR, Cockburn JG, Mulligan LM (2012). Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease. Human Mutation. Epub July 26, 2012.
Richardson DS, Rodrigues DM, Hyndman BD, Crupi MJF, Nicolescu AC, Mulligan LM (2012). Alternative splicing results in RET isoforms with distinct trafficking properties. Molec Biol Cell. 23 (19): 3838-3850. Epub Aug 8, 2012
Cockburn JG, Richardson DS, Mulligan LM (2010). RET-mediated cell-migration and adhesion require multiple integrin subunits. J Clin Endo Metab. 95 (11): E342-E346. Epub Aug 11, 2010.
Richardson DS, Mulligan LM (2010). Surface biotinylation for the visualization of internalization and recycling of membrane proteins. Journal of Fluorescence 20 (1): 401-405.
Toledo RA, Wagner SM, Coutinho FL, Lourenço DM, Arantes J, Rocha MP, Reis MTA, Pellucci LA, Longuini VC, Lucon AM, Tavares MR, Villares MCVB, Pereira AA, Dahia PL, Mulligan LM, Toledo SPA (2010). High penetrance of pheochromocytoma associated with the novel C634Y-Y791F double germline mutation in the RET protooncogene. Journal of Clinical Endocrinology & Metabolism. 95 (3): 1318-1327.
Hickey JG, Myers SM, Tian X, Zhu SJ, Shaw JLV, Andrew SD, Richardson DS, Brettschneider J, Mulligan LM (2009). RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation. Genes Chromosomes and Cancer 48: 429-440.
Richardson DS, Gujral TS, Peng S, Asa SL, Mulligan LM (2009). Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins. Cancer Research 69 (11): 4861-4869.
Gujral, TS, van Veelen W, Richardson DS, Myer SM, Meens JA, Acton DS, Duñach M, Elliott BE, Höppener JWM, and Mulligan LM (2008). A novel RET kinase-β-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Research 68 (5): 1338-1346.
updated: 20 Nov 2012